Skip to Main Content
Table 1

CD4 T Cells Mediate the Eosinophilic Response Induced by RSV G Protein and Peptide 19–KLH

Vaccine AntigenAntibody treatmentPercentage of CD4+ cellsPercentage of CD8+ cellsPercentage of  BAL eosinophils
G protein  rat Ig  21.2   8.5  67.2 ± 8.5 
G protein  anti-CD4   1.5  15.0   8.1 ± 4.7** 
G protein  anti-CD8  24.4   2.7  63.8 ± 6.4 
Peptide 19–KLH  rat Ig  19.0   7.7  29.6 ± 13.3 
Peptide 19–KLH  anti-CD4   0.3  20.0  0.75 ± 0.6** 
Peptide 19–KLH  anti-CD8  27.4   2.8  32.8 ± 10.3 
RSV  none  25.8  11.2   0.7 ± 1.0 
Vaccine AntigenAntibody treatmentPercentage of CD4+ cellsPercentage of CD8+ cellsPercentage of  BAL eosinophils
G protein  rat Ig  21.2   8.5  67.2 ± 8.5 
G protein  anti-CD4   1.5  15.0   8.1 ± 4.7** 
G protein  anti-CD8  24.4   2.7  63.8 ± 6.4 
Peptide 19–KLH  rat Ig  19.0   7.7  29.6 ± 13.3 
Peptide 19–KLH  anti-CD4   0.3  20.0  0.75 ± 0.6** 
Peptide 19–KLH  anti-CD8  27.4   2.8  32.8 ± 10.3 
RSV  none  25.8  11.2   0.7 ± 1.0 

BALB/c mice (five mice per group) were vaccinated intramuscularly at 0 and 4 wk with natural G protein (1 μg) or 250 μg KLH containing 18 μg peptide 19, or intranasally with RSV (106 PFU). The indicated antibodies were administered intraperitoneally at 14 and 20 d after immunization. The mice were challenged with RSV the next day and pulmonary eosinophilia was assessed 7 d later. Data are presented as mean percentage eosinophils in BAL (± 1 SD), and percentage of CD4+ and CD8+ cells relative to total splenic lymphocytes. Significant differences (**) are indicated compared to control mice given rat IgG. A second experiment yielded similar results.  

Close Modal

or Create an Account

Close Modal
Close Modal